Malaria vaccines: the stage we are at

With over 1 million deaths annually attributed to malaria, an effective vaccine is an urgently needed intervention. However, the various stages of the malaria parasite lifecycle have differing protective immune mechanisms and clinical endpoints, and usually different, often polymorphic, antigens. Trials using an increasing variety of vaccine platforms and antigens are under way in an attempt to achieve this long-awaited goal.

[1]  Inacio Mandomando,et al.  Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial , 2004, The Lancet.

[2]  T. Monath,et al.  Viral vectors for malaria vaccine development , 2006, Vaccine.

[3]  A. Hill.  Pre-erythrocytic malaria vaccines: towards greater efficacy , 2006, Nature Reviews Immunology.

[4]  Weltgesundheitsorganisation.  World malaria report , 2005 .

[5]  A. Mccarthy.  Development , 1996, Current Opinion in Neurobiology.

[6]  V. A. Stewart,et al.  Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya. , 2007, Vaccine.

[7]  M. Theisen,et al.  A Plasmodium falciparum GLURP-MSP3 chimeric protein; expression in Lactococcus lactis, immunogenicity and induction of biologically active antibodies. , 2004, Vaccine.

[8]  A. Hill,et al.  A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[9]  D. Webster,et al.  Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[10]  B. Lowe,et al.  A Phase 2b Randomised Trial of the Candidate Malaria Vaccines FP9 ME-TRAP and MVA ME-TRAP among Children in Kenya , 2006, PLoS clinical trials.

[11]  P. Andersen.  Vaccine strategies against latent tuberculosis infection. , 2007, Trends in microbiology.

[12]  D. Webster,et al.  Durable Human Memory T Cells Quantifiable by Cultured Enzyme-Linked Immunospot Assays Are Induced by Heterologous Prime Boost Immunization and Correlate with Protection against Malaria1 , 2005, The Journal of Immunology.

[13]  S. Cousens,et al.  Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthethic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa , 2007 .

[14]  S. Hay,et al.  The Malaria Atlas Project: Developing Global Maps of Malaria Risk , 2006, PLoS medicine.

[15]  A. Thomas,et al.  Preclinical Evaluation of a Chimeric Malaria Vaccine Candidate in Montanide ISA 720®: Immunogenecity and Safety in Rhesus Macaques , 2006, Human vaccines.

[16]  C. Dye.  Global epidemiology of tuberculosis , 2006, The Lancet.

[17]  M. Fay,et al.  Phase 1 Study of Two Merozoite Surface Protein 1 (MSP142) Vaccines for Plasmodium falciparum Malaria , 2007, PLoS clinical trials.

[18]  Q. Bassat,et al.  Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial , 2005, The Lancet.

[19]  V. A. Stewart,et al.  Safety and Allele-Specific Immunogenicity of a Malaria Vaccine in Malian Adults: Results of a Phase I Randomized Trial , 2006, PLoS clinical trials.

[20]  S. Cousens,et al.  Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthetic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa. , 2007, Vaccine.

[21]  V. A. Stewart,et al.  Priming with an Adenovirus 35-Circumsporozoite Protein (CS) Vaccine followed by RTS,S/AS01B Boosting Significantly Improves Immunogenicity to Plasmodium falciparum CS Compared to That with Either Malaria Vaccine Alone , 2007, Infection and Immunity.

[22]  V. A. Stewart,et al.  Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research. , 2007, Vaccine.

[23]  M. Demoitié,et al.  Murine Immune Responses to Liver-Stage Antigen 1 Protein FMP011, a Malaria Vaccine Candidate, Delivered with Adjuvant AS01B or AS02A , 2006, Infection and Immunity.

[24]  Thomas A. Smith,et al.  Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children. , 2003, Vaccine.